Discordances between CTCs and tissue biopsy, as seen here in patients with HER2+ CTCs and EGFR+ CTCs, offer opportunities to explore alternative therapies as CTCs better represent the metastatic scenario than tumor tissue. Here, ERBB2 is linked to neoplasm.